Morgan Stanley Raises Price Target for BioNTech SE Amid Positive Clinical Trial Results
Morgan Stanley has slightly raised its price target for BioNTech SE (BNTX) from $125 to $126, maintaining an Overweight rating as part of broader biopharma coverage updates. BioNTech reported positive Phase 2 trial results for its drug trastuzumab pamirtecan (BNT323/DB-1303), showing a 49.3% objective response rate in previously checkpoint-treated patients.
Tickers: $BNTX
Topics: biotech stock clinical trial results HER2-targeting therapy Morgan Stanley analysis price target update